MedTrace Logo

Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19

NCT04542226 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 81

Last updated 2020-12-09

Study results available
· View outcomes & findings →

Summary

The study is designed as an open observational non-comparative study of Polyoxidonium®, lyophilizate for solution for injections and topical application, 12 mg in hospitalized patients with coronavirus disease (COVID-19).

Conditions

  • Infections, Coronavirus

Interventions

DRUG

Polyoxidonium

Polyoxidonium (azoximer bromide) is administered in the dose of 12 mg (contents of 2 vials) once daily intravenously (IV) for 3 days, then every other day intramuscularly (IM) on days 5-17 (the total treatment course is 10 injections)

Sponsors & Collaborators

  • NPO Petrovax

    lead INDUSTRY

Principal Investigators

  • Nikolay S. Dodonov · NPO Petrovax

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-31
Primary Completion
2020-07-15
Completion
2020-10-30

Countries

  • Belarus
  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04542226 on ClinicalTrials.gov